Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone512-501-2444
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
Next Earnings Date11/4/2019 (Estimated)
OptionableNot Optionable
Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions
What is Cassava Sciences' stock symbol?
Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."
When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?
Shares of Cassava Sciences reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.
How were Cassava Sciences' earnings last quarter?
Cassava Sciences Inc (NASDAQ:SAVA) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.05. View Cassava Sciences' Earnings History.
When is Cassava Sciences' next earnings date?
What price target have analysts set for SAVA?
2 analysts have issued 12 month price targets for Cassava Sciences' stock. Their predictions range from $3.00 to $3.00. On average, they expect Cassava Sciences' share price to reach $3.00 in the next year. This suggests a possible upside of 172.7% from the stock's current price. View Analyst Price Targets for Cassava Sciences.
What is the consensus analysts' recommendation for Cassava Sciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cassava Sciences.
What are Wall Street analysts saying about Cassava Sciences stock?
Here are some recent quotes from research analysts about Cassava Sciences stock:
- 1. According to Zacks Investment Research, "Cassava Sciences Inc. is focused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer's. Cassava Sciences Inc., formerly known as Pain Therapeutics Inc., is based in Austin, United States. " (10/17/2019)
- 2. Maxim Group analysts commented, "Cassava announced the initiation of Phase 2b for its lead therapeutic candidate PTI-125 in mild-moderate Alzheimer’s disease (AD). The first two patients of the trial have been dosed. The Phase 2b initiation follows positive Phase 2a results (see note 9/9, LINK) in which a 100% responder rate and statistically significant reductions (p<0.001) in key AD biomarkers were noted, including an improved cerebrospinal fluid (CSF) P-tau to Aβ42 ratio (p<0.001), which has been found to correlate with cognitive deficiencies."" (9/18/2019)
- 3. HC Wainwright analysts commented, "Our $3 PT was derived by using a weighted- average cost of capital of 13% for Cassava shares to discount free cash flows from our projection of annual sales of PTI-125 in Alzheimer’s disease, and dividing them by our projected number of shares for each year to account for the effects of share dilution." (8/16/2019)
Has Cassava Sciences been receiving favorable news coverage?
Media stories about SAVA stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Cassava Sciences earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Cassava Sciences.
Are investors shorting Cassava Sciences?
Cassava Sciences saw a increase in short interest in September. As of September 15th, there was short interest totalling 1,780,000 shares, an increase of 8.5% from the August 15th total of 1,640,000 shares. Based on an average trading volume of 321,400 shares, the short-interest ratio is presently 5.5 days. Approximately 14.0% of the shares of the company are short sold. View Cassava Sciences' Current Options Chain.
Who are some of Cassava Sciences' key competitors?
Some companies that are related to Cassava Sciences include Chimerix (CMRX), Galmed Pharmaceuticals (GLMD), BioXcel Therapeutics (BTAI), Entasis Therapeutics (ETTX), Aduro BioTech (ADRO), NeuBase Therapeutics (NBSE), Aquestive Therapeutics (AQST), Humanigen (HGEN), Mersana Therapeutics (MRSN), Neoleukin Therapeutics (NLTX), vTv Therapeutics (VTVT), Lipocine (LPCN), Checkpoint Therapeutics (CKPT), Tiziana Life Sciences (TLSA) and Aravive (ARAV).
What other stocks do shareholders of Cassava Sciences own?
Who are Cassava Sciences' key executives?
Cassava Sciences' management team includes the folowing people:
- Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)
- Mr. Eric J. Schoen, Chief Financial Officer (Age 51)
- Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)
- Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs
Who are Cassava Sciences' major shareholders?
Cassava Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.31%). Company insiders that own Cassava Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, Eric Schoen and Sanford Robertson. View Institutional Ownership Trends for Cassava Sciences.
Which institutional investors are selling Cassava Sciences stock?
How do I buy shares of Cassava Sciences?
Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cassava Sciences' stock price today?
One share of SAVA stock can currently be purchased for approximately $1.10.
How big of a company is Cassava Sciences?
Cassava Sciences has a market capitalization of $18.94 million. The company earns $-6,560,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe.View Additional Information About Cassava Sciences.
What is Cassava Sciences' official website?
How can I contact Cassava Sciences?
Cassava Sciences' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]
MarketBeat Community Rating for Cassava Sciences (NASDAQ SAVA)
MarketBeat's community ratings are surveys of what our community members think about Cassava Sciences and other stocks. Vote "Outperform" if you believe SAVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
